This trial is testing a new cancer drug to see if it is safe and effective for people with lung cancer.
- Non-Small Cell Lung Cancer
3 Primary · 11 Secondary · Reporting Duration: Part B, C: From first dose of AZD2936 to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
Awards & Highlights
5 Treatment Groups
Dose Expansion Part C: CPI Naive NSCLC
1 of 5
Dose Expansion Part D: To be confirmed through a protocol amendment
1 of 5
Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced NSCLC
1 of 5
Dose Expansion Part D: CPI Naive NSCLC
1 of 5
Dose Expansion Part B: CPI experienced NSCLC
1 of 5
192 Total Participants · 5 Treatment Groups
Primary Treatment: AZD2936 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18 - 130 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the current sample size for participants in this trial?
"Affirmative, the current status of the study according to clinicaltrials.gov is actively recruiting participants. This medical research was initially presented on September 14th 2021 and has since been updated as recent as November 16th 2022. A total of 147 individuals are expected to be recruited from 4 distinct sites." - Anonymous Online Contributor
Are there any unfilled opportunities for patients to join this clinical trial?
"Clinicaltrials.gov reveals that this clinical trial is currently enrolling patients, having first been listed on September 14th 2021 and most recently updated November 16th 2022." - Anonymous Online Contributor
What is the goal of this scientific investigation?
"The primary endpoint of this clinical trial, which is expected to last for around two years, will measure the rate at which patients discontinue AZD2936 due to toxicity. Secondary objectives include analysis of the drug's pharmacokinetic clearance, objective response rate (ORR), and progression-free survival (PFS)." - Anonymous Online Contributor
Which demographic is ideal for inclusion in the trial?
"To qualify for this clinical trial, patients are required to have nsclc and be between 18-130 years old. An approximate total of 147 individuals need to partake in the study." - Anonymous Online Contributor
Does this trial include individuals aged 65 and above?
"This medical trial is seeking to enrol individuals aged 18 or above, but not exceeding 130 years old." - Anonymous Online Contributor
In what ways is this experiment being administered across multiple facilities?
"Presently, 4 centres are enrolling participants in this clinical trial. These sites can be found across Rochester, Chicago and Orange as well as a few other areas. It is best to select the closest medical centre to avoid any unnecessary travel if accepted into the scheme." - Anonymous Online Contributor